Breaking News

Ingenza set to celebrate 20th anniversary

The milestone will be marked with an event on the 20th of April for esteemed colleagues and guests

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life

Biggest overhaul of trial regulation for 20 years

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners

Advancing respiratory health through innovation

Beatriz Noriega Fernandes, PhD, Senior Principal Scientist at Lonza, describes how a QbD and DoE approach was taken to optimise the production proc...

Hovione enters partnership with Ripple Therapeutics

The move is set to expand the use of Ripple's Epidel platform beyond ophthalmic applications

Leucid Bio enters manufacturing agreement with Great Ormond Street

The company expects to file its Clinical Trial Application (CTA) to initiate clinical trials in H1 2023

What does 2023 hold for oral solid dosage forms?

Recipharm’s Uwe Hanenberg, Head of Product Development, Oral Solid Dose, and Maria Lundin-Johnson, Head of Formulation Development, explore the lat...

Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment

Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use...

Synaffix expands licensing agreement with MacroGenics

The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion

Teknova and Sartorious announce gene therapy collaboration

The collaboration highlights two essential components necessary for the successful recovery of empty and full AAV capsids during anion-exchange (AE...

Expanding capacity through collaboration

Michael Earl, Director of Pharmaceutical Services at Owen Mumford, and Steven Kaufman, Vice President for Drug Delivery Systems, Stevanato Group, t...

Inspiration from unexpected places

How pharmaceutical companies can learn from advances in nicotine delivery

PCI expands biologics with Midwest “centre of excellence”

New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics

Increasing patient compliance with ion exchange excipient taste masking

With a significant number of individuals reporting that they find it difficult to swallow tablets or capsules, and more people admitting to not tak...

Pfizer enters into merger with Seagen

The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfilment of customary closing conditions

Enabling oligonucleotide therapeutics with precision targeting methods

Oligonucleotides are a rapidly growing class of therapeutics. This modality appears to offer highly favourable therapeutic characteristics such as...